Objective: The aim of the study was to evaluate the durability of efficacy of the Integrated Care (IC) program in a Swedish context. The IC program is a person-centered flexible assertive community treatment approach delivered through a novel mechanism: a resource group clinical microsystem for each patient.

Methods: All patients with schizophrenia in a Gothenburg urban-sector catchment area were randomly assigned to either the IC or the Rational Rehabilitation (RR) programs. Sixty-six patients were interviewed and assessed by independent interviewers before treatment, after treatment (24 months), and at follow-up (five years). Analysis was by intention to treat.

Results: At the five-year follow-up, significant improvements were noted in social functioning and consumer satisfaction in the IC group (N=35) compared with the RR group (N=31). No patients were lost to services in either program.

Conclusions: The major finding was the durability of efficacy of the IC program.

Download full-text PDF

Source
http://dx.doi.org/10.1176/appi.ps.201300164DOI Listing

Publication Analysis

Top Keywords

durability efficacy
12
efficacy integrated
8
integrated care
8
care schizophrenia
4
schizophrenia five-year
4
five-year randomized
4
randomized controlled
4
controlled study
4
study objective
4
objective aim
4

Similar Publications

Achievement of duodenal ulcer remission by vedolizumab in children with eosinophilic gastroenteritis.

Clin J Gastroenterol

January 2025

Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, 1-2 Shintoshin, Chuo-ku, Saitama, 3308777, Japan.

Eosinophilic gastrointestinal disorders (EGIDs) are treated with corticosteroids and food allergen elimination. However, treatment for refractory cases is not standardized. We demonstrate the efficacy of vedolizumab, an anti-α4β7 integrin agent, in 2 children with duodenal ulcers developed by non-eosinophilic esophagitis EGIDs.

View Article and Find Full Text PDF

Background: The combination therapy of the B-Raf proto-oncogene (BRAF) inhibitor dabrafenib and the mitogen-activated protein kinase kinase (MEK) inhibitor Trametinib has shown favorable outcomes in patients initially identified with BRAF mutations. However, there are currently no large-scale study data focusing on the use of a triple therapy regimen of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) plus dabrafenib and trametinib in patients with newly concomitant BRAF mutations after acquiring resistance to EGFR-TKIs. Our study aimed to explore the efficacy and safety of the triple therapy regimen through a multi-center real-world experience.

View Article and Find Full Text PDF

Background: The unrelenting emergence of SARS-CoV-2 variants has significantly challenged the efficacy of existing COVID-19 vaccines. Enhancing the stability and immunogenicity of the spike protein is critical for improving vaccine performance and addressing variant-driven immune evasion.

Methods: We developed an mRNA-based vaccine, RV-1730, encoding the Delta variant spike protein with the S6P mutation to enhance stability and immunogenicity.

View Article and Find Full Text PDF

Aim: To investigate the effectiveness of unconventional post space disinfection techniques, specifically Er:YAG laser, Temoporfin, and Carbon Nanoparticles (CNPs), in improving Martens hardness (MH), eliminating the smear layer (SL), and enhancing the push-out bond strength (PBS) of glass fiber posts in canal dentin.

Methods: An in vitro study was conducted utilizing 80 single-rooted extracted human teeth, which were decoronated and subjected to standardized root canal preparation. The teeth were equally distributed into four experimental groups: Group 1 (NaOCl + EDTA), Group 2 (Er: YAG laser + EDTA), Group 3 (Temoporfin + EDTA), and Group 4 (CNPs + EDTA).

View Article and Find Full Text PDF

Rearranged during transfection (RET) lung cancer - Update on targeted therapies.

Lung Cancer

January 2025

Department of Medical Oncology, Princess Alexandra Hospital, Woolloongabba, Queensland 4102, Australia; The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland 4059, Australia; Translational Research Institute, Woolloongabba, Queensland 4102, Australia. Electronic address:

The enhanced comprehension of the molecular pathways underpinning oncogenesis in non-small cell lung cancer (NSCLC) has led to the advancement of personalized treatment for individuals with actionable mutations using targeted therapies. The rearranged during transfection (RET) proto-oncogene, is critical in the embryonic development of various tissues, including renal, neural, and neuroendocrine tissue. RET fusions have been observed in approximately 1-2% of NSCLC cases.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!